Objective: To investigate the molecular underpinnings of thyroid cancer, preclinical cell line models are crucial; however, ;40% of these have been proven to be either duplicates of existing thyroid lines or even nonthyroid-derived lines or are not derived from humans at all. Therefore, we set out to establish procedures and guidelines that should proactively avoid these problems, which facilitated the creation of criteria to make valid preclinical models for thyroid cancer research.
differ from each other in clinical course, underlying tumor genetic changes and therapeutic options. The most common driver mutations found in PTC are BRAF (61.7%), RAS (12.9%), TERT promoter (9.4%), RET/PTC rearrangements (6.3%), EIF1AX (1.5%), PPM1D (1.2%), and CHEK2 (1.2%) (2) , whereas FTC includes RAS (45%), PAX8/PPARg (PPFP) rearrangements (35%), and the TERT promoter (11.4%) (3, 4) . PDTC involves the TERT promoter (40% to 52%), RAS (28%), BRAF (33%), EIF1AX (11%), TP53 (8% to 25%), and RET/PTC rearrangements (6% to 13%) (5-7); ATC includes TP53 (73%), TERT promoter (73%), BRAF (45%), RAS (24%), PIK3CA (18%), PTEN (15%), NF1 (9%), EIF1AX (9%), and STK11 (6%) (7, 8) . ATC differs from PDTC by the frequency of alterations in four pathways: PI3K/AKT/ mTOR (39% vs 11%), SWI/SNF chromatin remodeling (36% vs 6%), histone methyltransferases (24% vs 7%), and mismatch excision repair (12% vs 2%) (7, 9) .
WDTCs, usually managed by surgery and radioactive iodine remnant ablation and thyroxine replacement, have an excellent prognosis (.90% 5-year survival). For radioiodine refractory tumors (excluding medullary thyroid cancer), chemotherapy and targeted therapy options include: doxorubicin, cisplatin, lenvatinib, and sorafenib (1, 10) . In contrast, PDTC and ATC have a poorer prognosis, with little response to therapy with 5-year survivals of 62% and 5% (8, 11) , respectively. This is indicative of a true lack of understanding of the biological underpinnings of each thyroid tumor subytype.
To investigate therapy-resistant WDTCs, PDTC and ATC, preclinical models are needed that cover the entire spectrum of thyroid tumor types, including primary normal thyrocytes. Despite some limitations, human cell lines are essential for testing biological mechanisms and new therapies in vitro prior to moving forward into animal models. Unfortunately, studies have shown that 18 of 36 cell lines (40% thyroid) are either misidentified or cross-contaminated, a situation that continues to bedevil the field (12) . Even when cell lines have been characterized with unique short tandem repeat (STR) DNA profiles, there is no guarantee that they are descendent from a particular tumor, as those have often not been characterized in the first place. For example, the FTC origin of WRO (13) is questionable because one version of the cell line in distribution harbors a BRAF T1799A (V600E) mutation, which is specific to PTC (3, 14) , whereas another version is BRAF wild-type. Both WRO versions have unique STR profiles (14) , but the question remains: which version is the real WRO? Owing to problems such as this, the number of unique thyroid cell lines, especially FTC-derived lines, is quite small. Therefore, proper criteria need to be established to create new cell line models for research.
In vitro cell lines that are engrafted in immunecompromised mouse models often bear little resemblance to the original tumors, due to loss of tumor heterogeneity and the human microenvironment, or drug resistance mechanisms. Genetically engineered mouse models address this problem partially; however, they recapitulate neither the human microenvironment nor the genetic/epigenetic complexity of human tumors, and they tend to have amplified responses to novel drugs. These limitations contribute to the only 5% effectiveness rate of anticancer agents in phase III trials (15) .
As a response, new preclinical patient-derived tumor xenograft (PDTX) models have emerged (also called PDX models or avatars) (16) . PDTX models resemble the original patient tumor genetically, maintain cellautonomous heterogeneity, maintain tumor architecture with stromal elements, and display drug responses that correlate strongly with clinical data. However, this model also has limitations: long engraftment time (1 to 4 months), loss of extrinsic non-cell-autonomous heterogeneity, inability to test immune-based therapies (the mice are immunocompromised), and changes in tumor characteristics over passaging (17, 18) .
Thus, more models need to be created and they need to be well characterized and quality controlled during their creation process. In this study, we set out to demonstrate how one can apply common sets of experimental tests to primary tumor cell line models and PDTX models, which allow their unequivocal identification as specific human thyroid-derived lines (linked back to the original tissue/ cell of origin), as well as permitting biological response assessment and tumor genetic characterization.
Materials and Methods

Patients, cell lines, and PDTXs
Thyroid patient tissue was collected in accordance with Mayo Clinic Institutional Review Board protocol. LAM136 originated from an 81-year-old female (4.3-cm conventional PTC; T3N1bM0). EAM306 originated from a 59-year-old female (7.2-cm angioinvasive FTC; T3N0M0). SDAR1 and SDAR2 both originated from a 66-year-old male (6.3-cm widely invasive FTC with areas of de-differentiation, as well as epithelioid and spindle cell features; T4aN0M1). SDAR1 was derived from the primary tumor site and SDAR2 from locally invasive regions in the neck. JEM493 (and MC-Th-493) originated from a 75-year-old male (6.0-cm ATC; T4bN1aM1; microscopic PTC foci and mild lymphocytic thyroiditis were also present). THJ529 (and MC-Th-529) originated from a 45-year-old male (8-cm PDTC involving 16 of 37 lymph nodes; T3N1bMx). THJ560 (and MC-Th-560) originated from a 49-year-old female (6.5-cm ATC arising in association with PTC; T4bN1bMx). Information on these cell lines was made available to the Cellosaurus (web.expasy.org/cellosaurus/). LAM136, EAM306, and SDAR1 were previously published in reference to SCD1 expression (19) .
For PDTX only models, MC-Th-95 originated from a male patient who presented with rare squamous cell thyroid carcinoma (SCTC). MC-Th-374 originated from a female [4.5 cm follicular variant PTC (FVPTC); T3NxMx]. MC-Th-467 originated from a 68-year-old male (3-cm PDTC arising from insular carcinoma; T2N1aMx). MC-Th-491 originated from a 68-year-old female (3.5-cm ATC; T4bN1aMx). MC-Th-504 originated from a 59-year-old male (5-cm ATC in association with PTC; T4bN1aMx). MC-Th-524 originated from an 80-year-old male (8-cm ATC in association with PTC and poorly differentiated SCTC). MC-Th-562 originated from a 69-year-old male (6-cm ATC with sarcomatoid features).
Tissue processing and establishment of PDTXs
Tumor tissues were collected in RPMI 1640 (catalog no. 10-040-CV; Corning, Manassas, VA) and processed within 4 hours. Tissues were cut into 4 3 4 3 4-mm cubes and were allocated as follows, as applicable: (1) formalin fixation for paraffin embedding (FFPE); (2) cryogenically frozen in RPMI 1640 supplemented with 5% FBS (catalog no. 16000-044, lot no. 1891471; Life Technologies, Grand Island, NY) plus 5% dimethyl sulfoxide (catalog no. D2650; Sigma-Aldrich, St. Louis, MO) plus 200 mM trehalose dihydrate (catalog no. T0167; Sigma-Adrich) plus 1% penicillin-streptomycinamphotericin B (PSA; catalog no. 30-004-CI; Corning); (3) flash frozen in liquid nitrogen; (4) finely minced for primary culture; and (5) surgically implanted under anesthesia with 100 mL of Matrigel ® (catalog no. 354234; Corning) into 4-to 6-week-old athymic nude female mice (strain 069; Envigo, Indianapolis, IN) for PDTX models. The take rate of engraftment is usually between 1 and 4 months with attempts up to 6 months. Take heed that longer engraftments increase the risk of the tumors actually arising from lymphoma (20) . Epithelial founder generation models (G 0 ) were then passaged using 5 3 5 3 5-mm fragments into new mice (G 1 and so forth) for expansion and for cryogenically frozen stocks. Only 67 preselected tissues were attempted for generating PDTX models (29 (21) . The remaining primary cultures senesced and were deemed mortal or noncontinuous cell lines. Live phase images were taken at magnification 310 under bright field on EVOS FLc (Life Technologies). As controls, either benign or normal thyrocytes (would senesce between passage 5 and 8) were either propagated in aBROV medium or in DMEM/F12 (catalog no. 10-090-CV; Corning) supplemented with 5% FBS, 1 mM sodium pyruvate, 10 mM HEPES, 1% nonessential amino acids, 1 nM triiodo-L-thyronine (catalog no. T6397; Sigma-Aldrich), 8 ng/mL epidermal growth factor (catalog no. AF-100-15; PeproTech Rocky Hill, NJ), 5 mg/mL insulin-transferrin-sodium selenite (catalog no. 354350; Corning), 0.45 mg/mL iron(II) sulfate heptahydrate (catalog no. F8633; Sigma-Aldrich), and 1% PSA. For cost savings, the FBS and iron sulfate can be substituted with iron-fortified bovine calf serum (catalog no. SH3007203; HyClone Laboratories, Lohan, UT). Please note that switching between serums or even lot numbers also requires quality control to ensure reproducibility (21) .
DNA/RNA isolation and analysis
For FFPE patient and PDTX tissues, five-10 mm sections were cut and deparaffinized, followed by DNA extraction (QIAamp DNA FFPE tissue kit, catalog no. 56404; Qiagen, Hilden, Germany). For cell lines, confluent 10-cm plates were scraped and pelleted. DNA was isolated using Purelink ® genomic DNA kits (catalog no. K1820-01; Invitrogen, Carlsbad, CA). RNA was isolated for frozen tissues and cell lines using Purelink ® RNA mini kits (catalog no. 12183018A; Invitrogen, Waltham, MA).
STR testing was performed by the Mayo Clinic Medical Genome Facility Genotyping Core (Rochester, MN) using a custom-designed STR profile based on the Combined DNA Index System of 13 loci set by the Federal Bureau of Investigation in 2016 (strbase.nist.gov). The primer sequences were verified with University of California, Santa Cruz (UCSC) and National Center for Biotechnology Information (NCBI) databases and validated using Centre d'Étude du Polymorphisme Humain (CEPH) cell line DNA GM12328, which matched known results conducted by commercial kits. Centre d'Étude du Polymorphisme Humain (CEPH) control sample NA10847 was included with every processing run and used as a control for all markers. Additionally, the primer mix was balanced in the multiplex to reduce spill over between markers and to provide comparable signal strengths. For analysis, the homozygous or heterozygous peaks at the loci were identified via bin alignment and exclusion of artifact peaks, which include spectral bleed and stutter peaks. Stutter peaks arise from polymerase slippage and were considered irrelevant unless there was overlap with nearby alleles. Thus, for split peaks, control DNA was used to determine which split peak (first or last) was the correct peak. For confirmation of allele loss at specific loci, DNA samples were reassayed using the PowerPlex 16HS (catalog no. DC2101; Promega, Madison, WI) and independently evaluated externally by the Genetics Resources Core Facility at Johns Hopkins University.
For BRAF, RAS (codons 12, 13, and 61) and RET/PTC analysis, real-time PCR methods were used as previously described (22, 23) . PIK3CA (exons 9 and 20), TERT promotor mutations, and PAX8/PPARg fusion (PPFP) were analyzed using primers listed in Supplemental Table 1 . All amplicons were purified using Purelink ® PCR purification kits (catalog no. K310001; Invitrogen) and bidirectionally sequenced using Sanger sequencing (Big Dye Terminator v1.1) by the Mayo Clinic Medical Genome Facility Genotyping Core. For the remaining mutations (TP53, PTEN, NF1, EIF1AX), MSK-IMPACT screening was performed at Dr. J.A. Fagin's laboratory, as previously described (24) . For RT-PCR, cDNA was generated from 3 mg of RNA using a high-capacity cDNA reverse transcription kit (catalog no. 4368814; Applied Biosystems, Foster City, CA) and 100 ng of cDNA was amplified with a ThermalAce DNA polymerase kit (catalog no. 45-0116; Invitrogen) using primers listed in Supplemental Table 1 Immunohistochemistry FFPE tissues were cut into 5-mm sections, deparaffinized, and hydrated and antigen was retrieved for 25 minutes at pH 6.0 and blocked for 5 minutes with Dako diluent (S3022) (Dako, Carpinteria, CA). Immunocytochemistry for cell lines was performed at 75% confluence in four-well LaboratoryTek chamber slides coated with poly-D-lysine (Nunc, Roshester, NY). Fixation was done with 2% paraformaldehyde. Immunostaining was done for 1 hour with either lamin A/C (catalog no. NBP1-95336, RRID: AB_ 11034444, at 1:400; Novus Biologicals, Littleton, CO), cytokeratin (catalog no. M0821; Dako), predilute human CD45 (catalog no. GA75161-2, RRID: AB_2661839; Dako), mouse CD45 (catalog no. 05-1416, RRID: AB_10562966; Millipore) at 1:200, thyroid transcription factor-1 (TTF1; catalog no. M3575; Dako) at 1:50, thyroid-stimulating hormone receptor (TSHR; catalog no. ab13399) at 1:100 (Abcam, Cambridge, MA), and sodium iodide symporter (NIS; catalog no. MA5-12308, RRID: AB_10977040; Thermo Fisher Scientific) at 1:100. Normal thyroid tissue and cells were used as positive controls, and mouse pancreatic cancer tissue was used as a negative control. For detection, the EnVision dual-labeled polymer kit (Dako) was used for 30 minutes for anti-species secondary antibodies and stained with diaminobenzidine chromagen (DAB) for 5 minutes and then lightly counterstained with Gill I hematoxylin (Sigma-Aldrich) for 30 seconds before dehydration and mounting. Images were obtained at magnification 320 using an Aperio AT2 Scanscope (Leica Biosystems, Buffalo Grove, IL). Immunohistochemistry (IHC) scoring of thyroid markers was done using an algorithm in the ImageScope software (Leica Biosystems) based on signal intensity of weak (1+), moderate (2+) or strong staining (3+) with criteria of at least 20% positivity.
Growth curves
For growth curves, 20,000 cells per well were plated in 12-well plates (catalog no. 25-106; Genesee Scientific, San Diego, CA) and counted using a Coulter particle counter (Beckman Coulter, Brea, CA) at the following time points: 24 hours, 72 hours, 120 hours, and 168 hours. For tumorigenicity, cells were suspended in 50% Matrigel ® (catalog no. 354234; Corning) in thyroid media and subcutaneously injected on the right flank in either 4-to 6-week-old athymic nude female mice (strain 069; Envigo) or 4-to 6-week-old NOD scid gamma female mice (strain 005557; The Jackson Laboratory, Bar Harbor, ME). Tumors were measured once or twice per week using calipers, and volumes were calculated by 0.536 3 (length 3 width 3 height). Data were graphed using GraphPad Prism (GraphPad Software, La Jolla, CA). Population doubling time was calculated using the Doubling Time online software Cell calculator++ (available at: www. doubling-time.com/compute.php).
Databases
In addition to searching published references for information on thyroid cell lines, the following databases were also examined: Cellosaurus, American Type Culture Collection, German Collection of Microorganisms and Cell Cultures, Japanese Collection of Research Bioresources, European Collection for Cell Cultures, and Rikagaku Kenky usho. The following databases were also examined for PDTX models: Charles River, CrownBio, Wuxi AppTec, Horizon Discovery, The Jackson Laboratory, Center for Developmental Therapeutics, Champions Oncology, and Children's Oncology Group.
Results
Histology, morphology, and species verification
Tumor tissues from the patients and the derived PDTX tissues were either stained with hematoxylin and eosin (H&E) or pan-cytokeratin for visualization of tumor architecture and for verification of cytokeratin positivity in the thyroid. Phase images of corresponding immortal cell lines were captured to examine cellular morphology. WDTC-derived cell lines (LAM136 and EAM306) both expressed abundant cytokeratin, whereas the invasive FTC-derived lines SDAR1 and SDAR2 showed somewhat lesser cytokeratin expression [ Fig. 1(a) ]. The ATC-derived cell lines JEM493 and THJ560 [ Fig. 1(b) ] and PDTC THJ529 are depicted with their corresponding PDTX models in Fig. 1(b) and 1(c) , respectively. The PDTX models (MC-Th-493, MC-Th-560, and MC-Th-529) showed similar histology and cytokeratin expression as their originating tumors. In addition to cytokeratin, the tumors were screened at G 0 for both human-specific CD45 and mouse-specific CD45 to ensure that the tumors did not arise from lymphomas as reported by Wetterauer et al. (20) in NOD scid gamma mice. Human spleen and mouse spleen were used as controls (data not shown). Lamin A/C expression confirmed that the tumor cells are of human origin. The mouse stroma was negative and murine pancreatic tumors were used as a negative control (inlay) [ Fig. 1(b) and 1(c) ]. Every PDTX generation (one to two individuals) was checked by H&E and for human lamin A/C expression to ensure integrity of the models. Using MCTh-529, we carried out the generations out farther up to G 8 and showed that the PDTX model conserved its histological phenotype and continued to express human lamin A/C [Supplemental Fig. 1(a) ].
Species content was further confirmed by qPCR on cDNA ranging from G 1 to G 8 tumors using either human-or murine-specific Src probes. The average absolute CT value was reported as well as the D between CT values for the species control and the PDTXs. DNA fingerprinting and thyroid markers STR analysis of all seven cell lines and 10 PDTX model profiles matched their originating tumor profiles (Table 1) . Also, all male-derived cell lines and PDTX models carried the amelogenin Y-allele. There were a few loss of heterogeneity (LOH) events observed at specific loci, which included both JEM493 and MC-Th-493 at locus TH01 with loss of variant allele 6, and MC-Th-467 at locus D21s11 with loss of variant allele 31.2 [ Table 1 ; Supplemental Fig. 2(a) Fig. 2(d) ]. These LOH events were verified by two independent facilities for confirmation.
Once human origin and authenticity were confirmed, three thyroid-specific differentiation markers were examined at mRNA and protein levels in the cell lines and their corresponding PDTX models. By RT-PCR of cell lines and PDTX models, TTF1 and TSHR mRNA was observed at various amounts whereas NIS mRNA was only seen in MC-Th-493 [ Fig. 2(a) ]. For IHC of patient tumor tissue, cell lines, and PDTX models, protein expression varied and did not necessarily resemble the mRNA levels. PDTX models more closely resembled the patients' expression pattern and intensity than did the cell lines [ Fig. 2(b) ]. Thus, both mRNA and protein levels were scored based on signal intensity and summarized for comparison [ Fig. 2(c) ]. LAM136, as expected, was the most differentiated as a PTC because it expressed both All male-derived cell lines and PDTX models carried the amelogenin Y-allele. a Locus data were inconclusive.
TTF1 and TSHR. The expression of TTF1 was to a lesser degree than the patient and despite having barely detectable TSHR mRNA; the protein expression was moderately expressed as in the patient. EAM306 only expressed TTF1, which was comparable to the patient. Both SDAR1 and SDAR2 only expressed TSHR, which was weaker than was seen in the patient despite having strong intensity levels of mRNA. JEM493 showed none of the three markers, whereas its PDTX counterpart expressed NIS comparable to the original patient. However, MC-Th-493 had moderate TSHR mRNA levels and had some small focal areas of positive staining (,20%) along with the patient. Despite having TSHR mRNA, THJ560 showed no TSHR at the protein level, whereas its corresponding PDTX expressed the receptor and the patient had some small focal areas of staining (,20%). THJ529 expressed comparable TSHR whereas TTF1 was reduced as compared with its PDTX counterpart and the original patient regardless of mRNA levels (Fig. 2) . To examine whether thyroid marker differentiation changes over generations, we examined TTF1 in MC-Th-529 up to G 8 and did not see any changes in overall TTF1 expression levels [Supplemental Fig. 1(b) ]. Table 2 summarizes the common tumor genetic changes that we found in the cell lines and their corresponding PDTX models for comparison with the originating patient tumor. All models harbored TERT promoter mutations with C228T (EAM306, JEM493, MC-Th-493, THJ529, MC-Th-529, THJ560, and MCTh-560) and C250T (LAM136, SDAR1, and SDAR2) being mutually exclusive (4, 6) . Moreover, SDAR1 and SDAR2 had a homozygous C250T mutation as seen by a single peak detected by Sanger sequencing (Supplemental Fig. 3 ) and confirmed by MSK-IMPACT testing. An additional T349C mutation was detected in LAM136, EAM306, THJ560, and MC-Th-560 that was verified in the patient tumor source.
Common thyroid cancer mutations
In addition to the TERT mutations, LAM136 was also a BRAF T1799A mutant with TP53 C577T and
TP53
A599T mutations with only a 0.21 and 0.16 frequency, respectively. EAM306 was an NRAS A182G mutant and a TP53 G976T mutant. The partnered FTC cell line models SDAR1 and SDAR2 were both PTEN G160 and TP53 mutant. SDAR2 was a TP53 G648 mutant whereas SDAR1 was a TP53 G845C mutant that was not detected in the primary tumor site of the patient. However, by MSK-IMPACT testing, SDAR1 also had a low TP53 G648 allele frequency of 0.11, below the 15% to 16% required for Sanger sequencing detection. THJ529 and its PDTX both harbor a BRAF T1799A mutation, but only the cell line had an additional TP53 C722G mutation.
JEM493 and its PDTX both only have an HRAS A182G mutation whereas THJ560 and its PDTX have BRAF T1799A mutations and TP53 G820T mutations. EIF1AX, RET/PTC, and PPFP were also examined and were wild-type in both the cell lines and three PDTX models.
Growth rates and tumorigenicity
All seven cell lines were examined for population doubling time and tumorigenicity. In vitro, EAM306 and JEM493 were the most rapidly proliferating cell lines with doubling times ,30 hours, whereas THJ529 was the slowest with a doubling time of 55 hours [ Fig. 3(a) ]. For tumorigenicity, 2 million cells in 50% Matrigel ® were injected into the flanks of female athymic nude mice. The ATC lines (JEM493 and THJ560) grew rapidly in vivo with doubling times ,5 days whereas EAM306 (FTC) had a doubling time of 17 days. The remaining cell lines did not grow in vivo even when 10 million cells were injected into the flanks of female NOD scid gamma mice [ Fig. 3(b) ]. Only the undifferentiated patient tumors gave rise to both cell lines and PDTX models (MC-Th-493, MCTh-529, and MC-Th-560) within the 1-to 4-month time frame. Tumor volumes were measured once or twice weekly, with volumes between 600 and 800 mm 3 for each generation after tumor implantation as time to endpoint (TTE). The most rapidly growing tumor, MC-Th-493, had an initial G 0 TTE of 41 days, whereas succeeding propagation generations ranged from 14 to 23 days [ Fig. 3(c) ]. MC-Th-529 for multiple generations sustained a TTE ;73 to 75 days until G 5, which had a change in growth (.10 days) of 49 days. Later generations in MC-Th-560 were not accessed, but the G 0 TTE was 55 days followed by a G 1 TTE of 39 days. An earlier model, MC-Th-95, was initially incubated past the 4-month time frame and had increased growth with the subsequent generations that ranged from 62 to 82 days. MC-Th-374 had an initial G 0 of 179 days whereas the subsequent generations ranged from 120 to 127 days [ Fig.  3(c) ]. As seen in the other PDTX models (MC-Th-467, MCTh-491, MC-Th-504, MC-Th-524, and MC-Th-562) the Mutations for TP53, PTEN, NF1, and EIF1AX were determined by MSK-IMPACT testing. EIF1AX, RET/PTC, and PAX8/PPARg (PPFP) were wild-type in all models.
Abbreviation: WT, wild-type. a Low allelic frequencies (,0.16), which may not be detectable via Sanger sequencing.
b Nonsense mutation.
c Homozygous mutation as seen by a single peak detected by Sanger sequencing and confirmed by MSK-IMPACT testing.
initial G 0 incubation was . For EAM306, JEM493, and THJ560, 2 million cells in 50% Matrigel ® were injected into the flanks of female athymic nude mice. LAM136, SDAR1, SDAR2, and THJ529 did not grow even when 10 million cells were injected into the flanks of female NOD scid gamma mice. (c) In vivo growth curves of PDTX models surgically implanted with 5 3 5 3 5-mm fragments and 100 mL of Matrigel ® into the flanks of athymic nude female mice are shown with the indicated generation TTE in days after tumor implantation. Endpoint was defined as a tumor volume between 600 and 800 mm 3 . Tumors were measured once or twice weekly with calipers. Data are graphed as mean volume 6 SE (n = 5). Most of the PDTX models were established within the 1-to 4-mo range with attempts up to 6 mo in two earlier models. n/a, not tested; -, tumor growth was not determined. Tables 1 and 2 ). To further validate our approach, we have also performed a comprehensive online search for all thyroid cell line models that have been at the minimum characterized and STR profiled or karyotyped as valid models (14, 23, 26, 27 (27) , and the newly characterized JEM493 and THJ560.
These cell lines are summarized in Table 3 (28-61). Our study also confirmed that PDTX models better represented the patient with regard to differential expression of thyroid markers (Fig. 2) and mutations ( Table 2) . For example, MC-Th-529 was TP53 wild-type similar to the patient, but the cell line harbored a TP53 C722G mutation that could have been either a subclone of the tumor tissue that would be difficult to detect by Sanger sequencing, or it might have been selected for two-dimensional cell culture. The PDTX models were characterized in similar fashion to the cell line models with the addition of quality control checkpoints. This was particularly important because PDTX models can be used as "avatars" for personalized medicine and as a screening platform for phase I clinical trials because they mimic clinical response to therapy (62) . Thus, one to two individual mice for every generation were randomly checked for species content and heterogeneity for quality control ( Fig. 1; Supplemental Fig. 1 ). This was particularly important because during subsequent generations, growth rate can change and the murine Src content in the PDTX models can increase as seen particularly in MC-Th-95 and MC-Th-529 [ Figs. 1(d) and 3(c) ]. With that said, the human Src content and human lamin A/C expression did not deviate ( Fig. 1; Supplemental Fig. 1 ), so these PDTX models were still valid. In our experience with multiple tissue types, species content can change over generations and even completely lose human content when the initial engraftment reached 6 months (data not shown). More studies need to be conducted to explore this observation. Also, slower engraftments increase the risk of the tumors arising from lymphomas (20) . Thus, to minimize the risk, engraftment time of PDTX models needs to be limited to the recommended 4 months and maintained at low passage or generation numbers to preserve genetic integrity of the original tumor (,G 10 ) (17) . The 10 PDTX model success rate in athymic nude mice was 14.9%. Most of the models consisted of the anaplastic subtype (six models, 75% success) and the others included one FVPTC (14.2% success), one PDTC, one SCTC, and one insular TC with no success in FTC and conventional PTC. To our knowledge, there is only one other published thyroid PDTX model, which was of the anaplastic subtype, and it was used for therapy screening (63) . Our group deposited 6 of the 10 newly developed models at Charles River Laboratories (www2.criver. com/l/60962/2016-07-13/9rjvzc). Another repository, CrownBio, also has seven thyroid PDTX models available. Champions Oncology did not have a publicly accessible database so we could not confirm whether thyroid PDTX models were deposited. Regardless, to improve the oncology problem of only a 5% efficacy in clinical trials (15) , more translationally relevant PDTX models for thyroid cancer need to be developed, especially for the refractory papillary, follicular, Hürthle cell, poorly differentiated, and completely dedifferentiated anaplastic subtypes.
In conclusion, having a large resource of validated cell lines and PDTX models that cover the many unique mutation signatures found in patient thyroid tumors would enhance development of therapeutic options for radioiodine refractory and chemotherapy-resistant thyroid cancers. Furthermore, validating STR profiles back to the originating tumor source should be regularly practiced for verifying identification.
